ambroxol has been researched along with Bronchitis in 35 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Bronchitis: Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol, oral solution, versus Ascoril Expectorant, syrup (combination of bromhexine, guaifenesin, and salbutamol) in the treatment of productive cough in adult patients with acute bronchitis." | 9.69 | [Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronch ( Esaulova, NA; Leshchenko, IV; Viktorova, IA; Zaitsev, AA, 2023) |
| " (4 x 300 mg, day 1-14), cefuroxime (CAS 55268-75-2) (2 x 250 mg daily for day 1-6), ambroxol (CAS 18683-91-5) (3 x 30 mg for day 1-3, 2 x 30 mg for days 4-14) and matched placebo in acute bronchitis." | 9.09 | Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. ( Carls, C; de Mey, C; Geib, A; Matthys, H; Ryś, A; Wittig, T, 2000) |
| "This study was designed to examine the efficacy and tolerability of ambroxol (Ambrosol) on the symptomatology of chronic bronchitis among in- and out-patients." | 9.08 | [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis]. ( Michnar, M; Milanowski, J, 1996) |
| "A comparison between the action of Ambroxol and Acetylcysteine was carried out in 28 children aged 2 to 13 (mean 7 years 3 months) affected with spastic bronchitis." | 9.06 | [A controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children]. ( Baldini, G; Gucci, M; Memmini, C; Tarò, D, 1989) |
| "In a double-blind, randomized, controlled trial using parallel groups, we evaluated the effects of two dose levels of ambroxol (60 and 120 mg daily) versus placebo by means of pulmonary function tests, patients' diary cards, interviews on current airway symptoms and subjective drug effects in 92 subjects with simple hypersecretory chronic bronchitis." | 9.06 | Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. ( Ericsson, CH; Jönsson, E; Juhasz, J; Mossberg, B, 1987) |
| "In a 6-month, double-blind multicenter trial conducted over the winter, the effects of daily administration of ambroxol retard (75 mg) were compared with those of placebo in preventing exacerbations and improving symptoms and clinical signs in chronic bronchitis patients." | 9.06 | Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. ( Bonsignore, G; Carnimeo, N; Catena, E; Chianese, R; Daniotti, S; Ferrara, G; Marcatili, S; Olivieri, D; Tomasini, G; Zavattini, G, 1987) |
| "Ambroxol is a mucolytic agent which is widely used in chronic bronchitis in Europe." | 9.06 | A controlled trial of ambroxol in chronic bronchitis. ( Guyatt, GH; Kazim, F; Newhouse, MT; Townsend, M, 1987) |
| "Twenty-three patients with exacerbations of chronic bronchitis were divided in two groups in a randomized fashion receiving either amoxicillin 1500 mg/d (n = 13) or amoxicillin 1500 mg/d associated with the mucolytic drug ambroxol 90 mg/d (n = 10)." | 9.06 | Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. ( Corazza, C; Fernández, M; Guerreiro, RB; Peralta, J; Poderoso, JJ; Wiemeyer, JC, 1987) |
| "To evaluate the efficacy and safety of Bronchosol® herbal syrup in comparison to ambroxol preparations in the treatment of acute bronchitis in adult patients." | 7.81 | [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study]. ( Fal, AM; Schönknecht, K, 2015) |
| "Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium." | 6.68 | Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. ( Capelli, A; Cerutti, CG; Donner, CF; Lusuardi, M; Salmona, M; Tacconi, MT, 1995) |
| "Ambroxol was associated with a 25% reduction of the average bronchial flow resistance." | 6.64 | [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)]. ( Niemeyer, K; Wiessmann, KJ, 1978) |
| "To evaluate the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol, oral solution, versus Ascoril Expectorant, syrup (combination of bromhexine, guaifenesin, and salbutamol) in the treatment of productive cough in adult patients with acute bronchitis." | 5.69 | [Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronch ( Esaulova, NA; Leshchenko, IV; Viktorova, IA; Zaitsev, AA, 2023) |
| " (4 x 300 mg, day 1-14), cefuroxime (CAS 55268-75-2) (2 x 250 mg daily for day 1-6), ambroxol (CAS 18683-91-5) (3 x 30 mg for day 1-3, 2 x 30 mg for days 4-14) and matched placebo in acute bronchitis." | 5.09 | Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. ( Carls, C; de Mey, C; Geib, A; Matthys, H; Ryś, A; Wittig, T, 2000) |
| "This study was designed to examine the efficacy and tolerability of ambroxol (Ambrosol) on the symptomatology of chronic bronchitis among in- and out-patients." | 5.08 | [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis]. ( Michnar, M; Milanowski, J, 1996) |
| "A comparison between the action of Ambroxol and Acetylcysteine was carried out in 28 children aged 2 to 13 (mean 7 years 3 months) affected with spastic bronchitis." | 5.06 | [A controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children]. ( Baldini, G; Gucci, M; Memmini, C; Tarò, D, 1989) |
| "In a double-blind, randomized, controlled trial using parallel groups, we evaluated the effects of two dose levels of ambroxol (60 and 120 mg daily) versus placebo by means of pulmonary function tests, patients' diary cards, interviews on current airway symptoms and subjective drug effects in 92 subjects with simple hypersecretory chronic bronchitis." | 5.06 | Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function. ( Ericsson, CH; Jönsson, E; Juhasz, J; Mossberg, B, 1987) |
| "In a 6-month, double-blind multicenter trial conducted over the winter, the effects of daily administration of ambroxol retard (75 mg) were compared with those of placebo in preventing exacerbations and improving symptoms and clinical signs in chronic bronchitis patients." | 5.06 | Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. ( Bonsignore, G; Carnimeo, N; Catena, E; Chianese, R; Daniotti, S; Ferrara, G; Marcatili, S; Olivieri, D; Tomasini, G; Zavattini, G, 1987) |
| "Ambroxol is a mucolytic agent which is widely used in chronic bronchitis in Europe." | 5.06 | A controlled trial of ambroxol in chronic bronchitis. ( Guyatt, GH; Kazim, F; Newhouse, MT; Townsend, M, 1987) |
| "Twenty-three patients with exacerbations of chronic bronchitis were divided in two groups in a randomized fashion receiving either amoxicillin 1500 mg/d (n = 13) or amoxicillin 1500 mg/d associated with the mucolytic drug ambroxol 90 mg/d (n = 10)." | 5.06 | Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. ( Corazza, C; Fernández, M; Guerreiro, RB; Peralta, J; Poderoso, JJ; Wiemeyer, JC, 1987) |
| " N-acetylcysteine (NAC-600 mg/day) and ambroxol (AMB-90 mg/day) were administered according to a double-blind cross-over scheme to 12 heavy smokers suffering from hypersecretory bronchitis and homogeneous reduction of the MCT." | 5.05 | Improvement of mucociliary transport in smokers by mucolytics. ( Del Donno, M; Marsico, SA; Olivieri, D, 1985) |
| "Ambroxol is frequently used as mucolytic agent in respiratory diseases associated with increased mucus production like acute or chronic bronchitis." | 4.84 | Antiinflammatory properties of ambroxol. ( Beeh, KM; Beier, J; Esperester, A; Paul, LD, 2008) |
| "Nine hundred sixty-five pharmacy customers purchasing one of four branded ambroxol formulations (extended release capsules, adult syrup, pediatric syrup and soft pastilles) filled a questionnaire including a patient-adapted version of the Bronchitis Severity Scale, several questions on degree of impairment by acute cough, time to onset of symptom relief and duration of treatment." | 3.88 | Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. ( Beeh, KM; Gräter, H; Kardos, P; Michel, MC; Mueck, T; Sent, U, 2018) |
| "To evaluate the efficacy and safety of Bronchosol® herbal syrup in comparison to ambroxol preparations in the treatment of acute bronchitis in adult patients." | 3.81 | [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study]. ( Fal, AM; Schönknecht, K, 2015) |
| "The clinical activity of trans-4-[(2-amino-3,5-dibromo-benzyl)-amino]-cyclohexanol-hydrochloride (ambroxol, NA 872) as well as its influence on lung function was examined in a total of 63 patients (34 suffering from silicosis, 28 from chronic obstructive bronchitis and 1 from cryptococcosis)." | 3.66 | [Therapeutic study on ambroxol in chronic bronchopulmonary diseases (author's transl)]. ( Curti, PC; Renovanz, HD, 1978) |
| "In an open trial trans-4-[(2-amino-3,5-dibromo-benzyl)-amino]-cyclohexanol hydrochloride (ambroxol, NA 872) in the form of ambroxol syrup was given to non-hospitalised patients suffering from acute and chronic bronchitis." | 3.66 | [Clinical experience with ambroxol syrup (author's transl)]. ( Göbel, P; Rensch, H, 1978) |
| "Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium." | 2.68 | Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. ( Capelli, A; Cerutti, CG; Donner, CF; Lusuardi, M; Salmona, M; Tacconi, MT, 1995) |
| "Ambroxol was associated with a 25% reduction of the average bronchial flow resistance." | 2.64 | [Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)]. ( Niemeyer, K; Wiessmann, KJ, 1978) |
| "Erdosteine is a new homocysteine-derived expectorant and has been reported to have many mucolytic effects." | 1.30 | Erdosteine enhances mucociliary clearance in rats with and without airway inflammation. ( Hosoe, H; Kaise, T; Ohmori, K, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (65.71) | 18.7374 |
| 1990's | 5 (14.29) | 18.2507 |
| 2000's | 4 (11.43) | 29.6817 |
| 2010's | 2 (5.71) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Zaitsev, AA | 1 |
| Leshchenko, IV | 1 |
| Esaulova, NA | 1 |
| Viktorova, IA | 1 |
| Kardos, P | 1 |
| Beeh, KM | 2 |
| Sent, U | 1 |
| Mueck, T | 1 |
| Gräter, H | 1 |
| Michel, MC | 1 |
| Fal, AM | 1 |
| Schönknecht, K | 1 |
| Beier, J | 1 |
| Esperester, A | 1 |
| Paul, LD | 1 |
| Berni, M | 1 |
| Collina, A | 1 |
| Zavattini, G | 2 |
| von Seefeld, H | 1 |
| Weiss, JM | 1 |
| Rensch, H | 2 |
| Schöpp, W | 1 |
| Lusuardi, M | 1 |
| Capelli, A | 1 |
| Salmona, M | 1 |
| Tacconi, MT | 1 |
| Cerutti, CG | 1 |
| Donner, CF | 1 |
| Michnar, M | 1 |
| Milanowski, J | 1 |
| Betz, R | 1 |
| Serrano, J | 1 |
| Sanchis, J | 1 |
| Hosoe, H | 1 |
| Kaise, T | 1 |
| Ohmori, K | 1 |
| Matthys, H | 1 |
| de Mey, C | 1 |
| Carls, C | 1 |
| Ryś, A | 1 |
| Geib, A | 1 |
| Wittig, T | 1 |
| Ekberg-Jansson, A | 1 |
| Larsson, S | 1 |
| Löfdahl, CG | 1 |
| Aleksa, VI | 1 |
| Prozorova, VK | 1 |
| Mal'tseva, NA | 1 |
| Shatikhina, LN | 1 |
| Wiessmann, KJ | 1 |
| Niemeyer, K | 1 |
| Curti, PC | 1 |
| Renovanz, HD | 1 |
| Göbel, P | 1 |
| Kranicke, R | 1 |
| Baldini, G | 1 |
| Gucci, M | 1 |
| Tarò, D | 1 |
| Memmini, C | 1 |
| Solopov, VN | 3 |
| Lunichkina, IV | 1 |
| Plisko, LF | 2 |
| Aliperta, A | 1 |
| Bellissimo, U | 1 |
| Turco, D | 1 |
| Antinolfi, G | 1 |
| Kolganova, NA | 2 |
| Cegla, UH | 1 |
| Chuchalin, AG | 1 |
| Ericsson, CH | 3 |
| Juhasz, J | 3 |
| Jönsson, E | 2 |
| Mossberg, B | 3 |
| Olivieri, D | 2 |
| Tomasini, G | 1 |
| Daniotti, S | 1 |
| Bonsignore, G | 1 |
| Ferrara, G | 1 |
| Carnimeo, N | 1 |
| Chianese, R | 1 |
| Catena, E | 1 |
| Marcatili, S | 1 |
| Guyatt, GH | 1 |
| Townsend, M | 1 |
| Kazim, F | 1 |
| Newhouse, MT | 1 |
| Dirksen, H | 1 |
| Hermansen, F | 1 |
| Groth, S | 1 |
| Mølgaard, F | 1 |
| Disse, BG | 1 |
| Philipson, K | 1 |
| Svartengren, M | 1 |
| Camner, P | 1 |
| Peralta, J | 1 |
| Poderoso, JJ | 1 |
| Corazza, C | 1 |
| Fernández, M | 1 |
| Guerreiro, RB | 1 |
| Wiemeyer, JC | 1 |
| Marsico, SA | 1 |
| Del Donno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ambroxol and Bronchitis
| Article | Year |
|---|---|
Antiinflammatory properties of ambroxol.
Topics: Administration, Oral; Ambroxol; Anti-Inflammatory Agents; Bronchitis; Humans; Inflammation; Pharyngi | 2008 |
[Usefulness of mucoactive drugs in respiratory diseases].
Topics: Acetylcysteine; Ambroxol; Bromhexine; Bronchiectasis; Bronchitis; Cystic Fibrosis; Deoxyribonuclease | 1998 |
The pharmacology of ambroxol--review and new results.
Topics: Airway Resistance; Ambroxol; Animals; Bromhexine; Bronchitis; Chronic Disease; Humans; Infant, Newbo | 1987 |
19 trials available for ambroxol and Bronchitis
| Article | Year |
|---|---|
[Evaluation of the efficacy and safety of a combination drug containing ambroxol, guaifenesin, and levosalbutamol versus a fixed-dose combination of bromhexine/guaifenesin/salbutamol in the treatment of productive cough in adult patients with acute bronch
Topics: Acute Disease; Adult; Albuterol; Ambroxol; Bromhexine; Bronchitis; Cough; Drug Combinations; Expecto | 2023 |
Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol.
Topics: Ambroxol; Bronchi; Bronchitis; Bronchoalveolar Lavage Fluid; Chronic Disease; Double-Blind Method; E | 1995 |
[Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis].
Topics: Administration, Oral; Adult; Aged; Ambroxol; Anti-Bacterial Agents; Bronchitis; Chronic Disease; Cou | 1996 |
Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambroxol; Bronchitis; Bronchodilator Agents; Cefuroxime; Cep | 2000 |
[Clinical results in the treatment of chronic obstructive bronchitis with ambroxol in comparison with bromhexine (author's transl)].
Topics: Adult; Aged; Airway Resistance; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials a | 1978 |
[A controlled study on the action of a new formulation of ambroxol in asthmatiform bronchitis in children].
Topics: Acetylcysteine; Adolescent; Ambroxol; Bromhexine; Bronchitis; Child; Child, Preschool; Clinical Tria | 1989 |
[Effectiveness of lasolvan and bromhexine in chronic nonspecific lung diseases].
Topics: Ambroxol; Asthma; Bromhexine; Bronchitis; Clinical Trials as Topic; Humans; Mucociliary Clearance; P | 1989 |
Prevention of chronic bronchitis exacerbations with ambroxol (mucosolvan retard). An open, long-term, multicenter study in 5,635 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Doubl | 1989 |
[Comparative evaluation of the effectiveness of lasolvan and mucodine in chronic nonspecific lung diseases].
Topics: Ambroxol; Asthma; Bromhexine; Bronchitis; Carbocysteine; Chronic Disease; Clinical Trials as Topic; | 1988 |
[Long-term therapy over 2 years with ambroxol (Mucosolvan) retard capsules in patients with chronic bronchitis. Results of a double-blind study of 180 patients].
Topics: Administration, Oral; Adult; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as T | 1988 |
[Effect of lasolvan on the rheologic properties of sputum].
Topics: Ambroxol; Asthma; Bromhexine; Bronchitis; Clinical Trials as Topic; Humans; Sputum | 1987 |
Ambroxol and simple chronic bronchitis. Effects on subjective symptoms and ventilatory function.
Topics: Adult; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1987 |
Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo.
Topics: Adult; Ambroxol; Bacterial Infections; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as T | 1987 |
A controlled trial of ambroxol in chronic bronchitis.
Topics: Ambroxol; Bromhexine; Bronchitis; Clinical Trials as Topic; Double-Blind Method; Expectorants; Femal | 1987 |
Mucociliary clearance in early simple chronic bronchitis.
Topics: Adult; Ambroxol; Bronchi; Bronchitis; Chronic Disease; Clinical Trials as Topic; Humans; Mucociliary | 1987 |
Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function.
Topics: Adult; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1986 |
Influence of ambroxol on tracheobronchial clearance in simple chronic bronchitis.
Topics: Adult; Aged; Ambroxol; Bromhexine; Bronchitis; Cilia; Double-Blind Method; Female; Humans; Lung; Mal | 1987 |
Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis.
Topics: Adult; Aged; Aged, 80 and over; Ambroxol; Amoxicillin; Blood Gas Analysis; Bromhexine; Bronchitis; C | 1987 |
Improvement of mucociliary transport in smokers by mucolytics.
Topics: Acetylcysteine; Adult; Ambroxol; Biological Transport; Bromhexine; Bronchitis; Cilia; Double-Blind M | 1985 |
13 other studies available for ambroxol and Bronchitis
| Article | Year |
|---|---|
Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations.
Topics: Adolescent; Adult; Ambroxol; Bronchitis; Child; Child, Preschool; Cough; Dosage Forms; Drug Compound | 2018 |
[Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study].
Topics: Acute Disease; Adult; Ambroxol; Antitussive Agents; Bronchitis; Cough; Expectorants; Female; Humans; | 2015 |
[Ambroxol in bronchopulmonary pathology in children].
Topics: Ambroxol; Bromhexine; Bronchial Diseases; Bronchitis; Carbocysteine; Child; Child, Preschool; Cough; | 1983 |
[New concepts in the therapy of mucostasis].
Topics: Ambroxol; Animals; Bromhexine; Bronchitis; Humans; Mucus; Pulmonary Surfactants | 1983 |
[Long-term treatment of chronic bronchitis with ambroxol].
Topics: Adult; Aged; Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Drug Administration Schedule; Drug E | 1981 |
[Glucocorticosteroids and ambroxol inhibit secretion of inflammatory cytokines in tracheobronchial epithelial cells: Possible role of the NF-kappa B transcription factor].
Topics: Ambroxol; Asthma; Bronchitis; Culture Techniques; Dexamethasone; Epithelium; Expectorants; Glucocort | 1997 |
Erdosteine enhances mucociliary clearance in rats with and without airway inflammation.
Topics: Albumins; Ambroxol; Animals; Bronchi; Bronchitis; Bronchoalveolar Lavage Fluid; Carbocysteine; Carbo | 1998 |
Preventing exacerbations of chronic bronchitis and COPD.
Topics: Acetylcysteine; Adjuvants, Immunologic; Ambroxol; Antioxidants; Bacteria; Bronchitis; Cell Extracts; | 2001 |
[Effectiveness of lasolvan in patients with chronic obstructive bronchitis and non-atopic bronchial asthma].
Topics: Adult; Ambroxol; Asthma; Bronchitis; Chronic Disease; Expectorants; Humans; Injections, Intramuscula | 2001 |
[Therapeutic study on ambroxol in chronic bronchopulmonary diseases (author's transl)].
Topics: Ambroxol; Bromhexine; Bronchitis; Chronic Disease; Cryptococcosis; Humans; Lung Diseases; Lung Disea | 1978 |
[Clinical experience with ambroxol syrup (author's transl)].
Topics: Administration, Oral; Adult; Aged; Ambroxol; Bromhexine; Bronchitis; Female; Humans; Male; Middle Ag | 1978 |
[Results of a clinical trial with ambroxol as to postoperative therapy of bronchitis (author's transl)].
Topics: Aged; Ambroxol; Bromhexine; Bronchitis; Drug Administration Schedule; Female; Humans; Injections, In | 1978 |
Normalization of bronchial exocrine pathology after endobronchial treatment with ambroxol.
Topics: Adult; Aged; Ambroxol; Biopsy; Bromhexine; Bronchi; Bronchitis; Bronchoscopy; Chronic Disease; Exocr | 1986 |